In re: Mylan Inc. et al
| Mylan Inc. and Mylan Pharmaceuticals Inc. |
| Somaxon Pharmaceuticals Inc., Procom One Inc., Currax Pharmaceuticals LLC, Currax Holdings LLC and Currax Holdings USA LLC. |
| 1:2022mc00501 |
| October 24, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Other Statutory Actions |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 5, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 18
ORAL ORDER: The motion to quash is DISMISSED as moot (see D.I. #17 ). Ordered by Judge Richard G. Andrews on 12/5/2022. (nms)
|
| Filing 17 Letter to The Honorable Richard G. Andrews, from Anthony D. Raucci, regarding Motion to Quash. (Raucci, Anthony) Modified on 12/5/2022 (nms). |
| CASE CLOSED per entry of D.I. 18 . (nms) |
| Filing 16 NOTICE of Appearance by Megan C. Haney on behalf of Mylan Inc., Mylan Pharmaceuticals Inc. (Haney, Megan) |
| Filing 15 NOTICE of Appearance by Anthony David Raucci on behalf of Currax Holdings LLC, Currax Holdings USA LLC., Currax Pharmaceuticals LLC (Raucci, Anthony) |
|
Filing 14
ORAL ORDER: In light of the dismissal of Somaxon v. Actavis, No. 10-1100-RGA-MPT, it appears this motion may be moot. Could the parties jointly advise whether the motion is moot, and, if it is not, explain why it is not. Ordered by Judge Richard G. Andrews on 10/25/2022. (nms)
|
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (nms) |
| Filing 13 Local Counsel Letter sent. Notice of Compliance deadline set for 11/23/2022. (smg) |
| Filing 12 Record of case transferred in from District of New Jersey; Case Number in Other District: 2:22-cv-03944. Copy of Docket Sheet and original file |
| Case extracted via ECF to District of Delaware. (mfr) [Transferred from New Jersey on 10/24/2022.] |
|
Filing 11
ORDER ADOPTING AND AFFIRMING REPORT AND RECOMMENDATIONS re ECF #10 , and Granting in part ECF #1 Motion to Quash solely to the extent that said Motion be transferred to the District of Delaware, where Civil Action No. 1:10-cv-01100 is pending. Signed by Judge Kevin McNulty on 10/21/2022. ***CIVIL CASE TERMINATED. (jd, ) [Transferred from New Jersey on 10/24/2022.]
|
| Filing 10 REPORT AND RECOMMENDATION re #1 MOTION to Quash; Objections, if any, to R&R due by 10/14/2022. Signed by Magistrate Judge James B. Clark on 9/30/2022. (jd, ) [Transferred from New Jersey on 10/24/2022.] |
| Filing 9 REPLY BRIEF to Opposition to Motion filed by MYLAN INC., MYLAN PHARMACEUTICALS INC., re #1 MOTION to Quash/Compel/Enforce Subpoenas ( Filing fee $ 49 receipt number ANJDC-13488658.) (Attachments: #1 Declaration of G. Edward Powell III, #2 Exhibit 1, #3 Certificate of Service)(CALMANN, ARNOLD) [Transferred from New Jersey on 10/24/2022.] |
| Filing 8 Corporate Disclosure Statement by Currax Holdings LLC, Currax Holdings USA LLC, Currax Pharmaceuticals LLC identifying Currax Holdings USA LLC and Currax Holdings LLC as Corporate Parent.. (AUSTIN, ERIN) [Transferred from New Jersey on 10/24/2022.] |
| Filing 7 AFFIDAVIT in Opposition filed by Currax Holdings LLC, Currax Holdings USA LLC, Currax Pharmaceuticals LLC re #1 MOTION to Quash/Compel/Enforce Subpoenas ( Filing fee $ 49 receipt number ANJDC-13488658.) (Attachments: #1 Exhibit A - Delaware Dismissal, #2 Exhibit B - Email from Mylan, #3 Exhibit C - Teva Subpoena Service, #4 Exhibit D - Notice of Subpoena, #5 Exhibit E - Email from Teva)(AUSTIN, ERIN) [Transferred from New Jersey on 10/24/2022.] |
| Filing 6 MEMORANDUM in Opposition filed by Currax Holdings LLC, Currax Holdings USA LLC, Currax Pharmaceuticals LLC re #1 MOTION to Quash/Compel/Enforce Subpoenas ( Filing fee $ 49 receipt number ANJDC-13488658.) (AUSTIN, ERIN) [Transferred from New Jersey on 10/24/2022.] |
| Filing 5 NOTICE of Appearance by ERIN AUSTIN on behalf of Currax Pharmaceuticals LLC, Currax Holdings LLC, Currax Holdings USA LLC (AUSTIN, ERIN) [Transferred from New Jersey on 10/24/2022.] |
| Filing 4 AMENDED DOCUMENT by MYLAN INC., MYLAN PHARMACEUTICALS INC.,. Amendment to #3 Notice of Appearance . (ALBIN, GERI) [Transferred from New Jersey on 10/24/2022.] |
| Filing 3 NOTICE of Appearance by GERI L. ALBIN on behalf of MYLAN INC., MYLAN PHARMACEUTICALS INC., (ALBIN, GERI) [Transferred from New Jersey on 10/24/2022.] |
| Filing 2 Corporate Disclosure Statement by MYLAN INC., MYLAN PHARMACEUTICALS INC.,. (CALMANN, ARNOLD) [Transferred from New Jersey on 10/24/2022.] |
| Filing 1 MOTION to Quash/Compel/Enforce Subpoenas ( Filing fee $ 49 receipt number ANJDC-13488658.), filed by MYLAN PHARMACEUTICALS INC.,, MYLAN INC.. (Attachments: #1 Brief, #2 Declaration G. Edward Powell, III, #3 Exhibit A, #4 Certification Pursuant to Local Rule 11.2, #5 Civil Cover Sheet, #6 Text of Proposed Order, #7 Certificate of Service)(CALMANN, ARNOLD) [Transferred from New Jersey on 10/24/2022.] Modified on 10/24/2022 to mark motion as pending.(smg). |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
